Enlivex Receives First FDA Approval For Phase2b Trial Of Allocetra For Age-Related Osteoarthritis

Enlivex has received FDA approval for its Investigational New Drug application for Allocetra, aimed at treating moderate-to-severe age-related symptomatic primary knee osteoarthritis. This marks the company's first FDA approval for a Phase 2b trial. The approval is a significant milestone for Enlivex as it advances its product development in the osteoarthritis market.